Skip to main content

Advertisement

Log in

Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?

  • Endocrine Methods and Techniques
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms with heterogeneous clinical behavior and potential long-term survival. In 2006/2007, the European Neuroendocrine Tumors Society introduced an important parameter, grade (based on mitoses and Ki-67 proliferation rate), which became part of the latest 2010-WHO classification. Since this is an important tool in the choice of therapeutic algorithm of patients with NETs, our aim was to audit whether retrospective reclassification is possible and feasible and correlate pathological findings with survival. From the histopathology archive, 338 GEP-NETs (1994–2014) were identified, of which 250 were diagnosed pre-2010 and 80 of these have needed, up till now, classification (morphology and grade—mitotic count/Ki-67). Morphology was well differentiated (WD) in 74 cases while only 6 cases were poorly differentiated (PD). Grade was reclassified: G1—45 cases (56 %); G2—28 cases (35 %); G3—7 cases (9 %). Overall survival (OS) in WD NETs was strikingly better compared to PD neoplasms. Differences in OS between grade were statistically significant (p < 0.0001) and, in particular, grade identified a subgroup of patients with WD lesions but with less favorable clinical behavior (OS at 5 years: G1—89 %; G2—48 %; G3—0 %; G1 vs G2 p = 0.03). Feasibility analysis quantified time for reclassification to be between 45 and 64 min/case. Our series confirms the importance of grade in prognostic stratification and underlines that reclassification is feasible, and may prove worthwhile in patient management, especially in view of the potential long survival of patients with NETs and risk of use of inappropriate therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. B.I. Gustafsson, M. Kidd, I.M. Modlin, Neuroendocrine tumors of the diffuse neuroendocrine system. Curr. Opin. Oncol. 20, 1–12 (2008)

    Article  PubMed  Google Scholar 

  2. I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, M. Caplin, G. Delle Fave, G.A. Kaltsas, E.P. Krenning, S.F. Moss, O. Nilsson, G. Rindi, R. Salazar, P. Ruszniewski, A. Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008)

    Article  CAS  PubMed  Google Scholar 

  3. C. Capella, E. Solcia, L.H. Sobin, in Pathology and genetics of tumours of the digestive system, ed. by S.R. Hamilton, L.A. Aaltonen (IARC Press, Lyon, 2000), pp. 77–82

    Google Scholar 

  4. G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard, W.W. de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Körner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, all other Frascati Consensus Conference participants, European Neuroendocrine Tumor Society (ENETS), TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. G. Rindi, G. Klöppel, A. Couvelard, P. Komminoth, M. Körner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451, 757–762 (2007)

    Article  CAS  PubMed  Google Scholar 

  6. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (eds.), WHO classification of tumours of the digestive system (IARC Press, Lyon, 2010), pp. 13–14

    Google Scholar 

  7. L. Sobin, M. Gospodarowicz, C. Wittekind (eds.), UICC/AJCC TNM classification of malignant tumours, 7th edn. (Wiley, New York, 2009)

    Google Scholar 

  8. U.F. Pape, H. Jann, J. Mueller-Nordhorn, A. Bockelbrink, U. Berndt, S.N. Willich, M. Koch, C. Röcken, G. Rindi, B. Wiedenmann, Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113, 256–265 (2008)

    Article  PubMed  Google Scholar 

  9. H. Jann, S. Roll, A. Couvelard, O. Hentic, M. Pavel, J. Mueller-Nordhorn, M. Koch, C. Roecken, G. Rindi, P. Ruszniewski, B. Wiedenmann, U.F. Pape, Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117, 3332–3341 (2011)

    Article  PubMed  Google Scholar 

  10. J. Strosberg, A. Nasir, D. Coppola, M. Wick, L. Kvols, Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Human Pathol. 40, 1262–1268 (2009)

    Article  Google Scholar 

  11. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, Cutsem E. Van, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, P. Tomassetti, M.E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, K. Öberg, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group, Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 10(364), 514–523 (2011)

    Article  Google Scholar 

  12. F. Grillo, S. Pigozzi, P. Ceriolo, P. Calamaro, R. Fiocca, L. Mastracci, Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem. Cell Biol. 144(1), 93–99 (2015)

    Article  CAS  PubMed  Google Scholar 

  13. V. Adsay, Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am. J. Surg. Pathol. 36, 1743–1746 (2012)

    Article  PubMed  Google Scholar 

  14. M.D. Reid, P. Bagci, N. Ohike, B. Saka, I. Erbarut Seven, N. Dursun, S. Balci, H. Gucer, K.T. Jang, T. Tajiri, O. Basturk, S.Y. Kong, M. Goodman, G. Akkas, V. Adsay, Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Modern Pathol. 28, 686–694 (2015)

    Article  Google Scholar 

  15. O. Basturk, Z. Yang, L.H. Tang, R.H. Hruban, V. Adsay, C.M. McCall, A.M. Krasinskas, K.T. Jang, W.L. Frankel, S. Balci, C. Sigel, D.S. Klimstra, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39, 683–690 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  16. E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.S. Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 10(364), 501–513 (2011)

    Article  Google Scholar 

  17. J.R. Strosberg, R.L. Fine, J. Choi, A. Nasir, D. Coppola, D.T. Chen, J. Helm, L. Kvols, First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 15(117), 268–275 (2011)

    Article  Google Scholar 

  18. K. Öberg, U. Knigge, D. Kwekkeboom, A. Perren, ESMO Guidelines Working Group, Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 Suppl 7, vii124–vii130 (2012)

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a University of Genoa Research Grant 2011 awarded to Dr. Grillo.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manuela Albertelli.

Ethics declarations

Conflict of interest

All authors declare that they do not have any conflicts of interest.

Additional information

Federica Grillo and Manuela Albertelli have contributed equally.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grillo, F., Albertelli, M., Annunziata, F. et al. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. Endocrine 53, 58–62 (2016). https://doi.org/10.1007/s12020-015-0734-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-015-0734-3

Keywords

Navigation